Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany

A retrospective model analysis

I. Müller, M. H. Freitag, G. Poggensee, E. Scharnetzky, E. Straube, Ch Schoerner, H. Hlobil, H. J. Hagedorn, G. Stanek, A. Schubert-Unkmeir, Douglas Norris, J. Gensichen, K. P. Hunfeld

Research output: Contribution to journalArticle

Abstract

Background. Data on the economic impact of Lyme borreliosis (LB) on European health care systems is scarce. This project focused on the epidemiology and costs for laboratory testing in LB patients in Germany. Materials and Methods. We performed a sentinel analysis of epidemiological and medicoeconomic data for 2007 and 2008. Data was provided by a German statutory health insurance (DAK) company covering approx. 6.04 million members. In addition, the quality of diagnostic testing for LB in Germany was studied. Results. In 2007 and 2008, the incident diagnosis LB was coded on average for 15,742 out of 6.04 million insured members (0.26). 20,986EIAs and 12,558 immunoblots were ordered annually for these patients. For all insured members in the outpatient sector, a total of 174,820EIAs and 52,280 immunoblots were reimbursed annually to health care providers (cost: 2,600,850). For Germany, the overall expected cost is estimated at 51,215,105. However, proficiency testing data questioned test quality and standardization of diagnostic assays used. Conclusion. Findings from this study suggest ongoing issues related to care for LB and may help to improve future LB disease management.

Original languageEnglish (US)
Article number595427
JournalClinical and Developmental Immunology
Volume2012
DOIs
StatePublished - 2012

Fingerprint

Lyme Disease
Germany
Costs and Cost Analysis
Health Insurance
Disease Management
Health Personnel
Health Care Costs
Epidemiology
Outpatients
Economics
Delivery of Health Care

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Müller, I., Freitag, M. H., Poggensee, G., Scharnetzky, E., Straube, E., Schoerner, C., ... Hunfeld, K. P. (2012). Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany: A retrospective model analysis. Clinical and Developmental Immunology, 2012, [595427]. https://doi.org/10.1155/2012/595427

Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany : A retrospective model analysis. / Müller, I.; Freitag, M. H.; Poggensee, G.; Scharnetzky, E.; Straube, E.; Schoerner, Ch; Hlobil, H.; Hagedorn, H. J.; Stanek, G.; Schubert-Unkmeir, A.; Norris, Douglas; Gensichen, J.; Hunfeld, K. P.

In: Clinical and Developmental Immunology, Vol. 2012, 595427, 2012.

Research output: Contribution to journalArticle

Müller, I, Freitag, MH, Poggensee, G, Scharnetzky, E, Straube, E, Schoerner, C, Hlobil, H, Hagedorn, HJ, Stanek, G, Schubert-Unkmeir, A, Norris, D, Gensichen, J & Hunfeld, KP 2012, 'Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany: A retrospective model analysis', Clinical and Developmental Immunology, vol. 2012, 595427. https://doi.org/10.1155/2012/595427
Müller, I. ; Freitag, M. H. ; Poggensee, G. ; Scharnetzky, E. ; Straube, E. ; Schoerner, Ch ; Hlobil, H. ; Hagedorn, H. J. ; Stanek, G. ; Schubert-Unkmeir, A. ; Norris, Douglas ; Gensichen, J. ; Hunfeld, K. P. / Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany : A retrospective model analysis. In: Clinical and Developmental Immunology. 2012 ; Vol. 2012.
@article{93892107402645df94858a3055f4acc0,
title = "Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany: A retrospective model analysis",
abstract = "Background. Data on the economic impact of Lyme borreliosis (LB) on European health care systems is scarce. This project focused on the epidemiology and costs for laboratory testing in LB patients in Germany. Materials and Methods. We performed a sentinel analysis of epidemiological and medicoeconomic data for 2007 and 2008. Data was provided by a German statutory health insurance (DAK) company covering approx. 6.04 million members. In addition, the quality of diagnostic testing for LB in Germany was studied. Results. In 2007 and 2008, the incident diagnosis LB was coded on average for 15,742 out of 6.04 million insured members (0.26). 20,986EIAs and 12,558 immunoblots were ordered annually for these patients. For all insured members in the outpatient sector, a total of 174,820EIAs and 52,280 immunoblots were reimbursed annually to health care providers (cost: 2,600,850). For Germany, the overall expected cost is estimated at 51,215,105. However, proficiency testing data questioned test quality and standardization of diagnostic assays used. Conclusion. Findings from this study suggest ongoing issues related to care for LB and may help to improve future LB disease management.",
author = "I. M{\"u}ller and Freitag, {M. H.} and G. Poggensee and E. Scharnetzky and E. Straube and Ch Schoerner and H. Hlobil and Hagedorn, {H. J.} and G. Stanek and A. Schubert-Unkmeir and Douglas Norris and J. Gensichen and Hunfeld, {K. P.}",
year = "2012",
doi = "10.1155/2012/595427",
language = "English (US)",
volume = "2012",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany

T2 - A retrospective model analysis

AU - Müller, I.

AU - Freitag, M. H.

AU - Poggensee, G.

AU - Scharnetzky, E.

AU - Straube, E.

AU - Schoerner, Ch

AU - Hlobil, H.

AU - Hagedorn, H. J.

AU - Stanek, G.

AU - Schubert-Unkmeir, A.

AU - Norris, Douglas

AU - Gensichen, J.

AU - Hunfeld, K. P.

PY - 2012

Y1 - 2012

N2 - Background. Data on the economic impact of Lyme borreliosis (LB) on European health care systems is scarce. This project focused on the epidemiology and costs for laboratory testing in LB patients in Germany. Materials and Methods. We performed a sentinel analysis of epidemiological and medicoeconomic data for 2007 and 2008. Data was provided by a German statutory health insurance (DAK) company covering approx. 6.04 million members. In addition, the quality of diagnostic testing for LB in Germany was studied. Results. In 2007 and 2008, the incident diagnosis LB was coded on average for 15,742 out of 6.04 million insured members (0.26). 20,986EIAs and 12,558 immunoblots were ordered annually for these patients. For all insured members in the outpatient sector, a total of 174,820EIAs and 52,280 immunoblots were reimbursed annually to health care providers (cost: 2,600,850). For Germany, the overall expected cost is estimated at 51,215,105. However, proficiency testing data questioned test quality and standardization of diagnostic assays used. Conclusion. Findings from this study suggest ongoing issues related to care for LB and may help to improve future LB disease management.

AB - Background. Data on the economic impact of Lyme borreliosis (LB) on European health care systems is scarce. This project focused on the epidemiology and costs for laboratory testing in LB patients in Germany. Materials and Methods. We performed a sentinel analysis of epidemiological and medicoeconomic data for 2007 and 2008. Data was provided by a German statutory health insurance (DAK) company covering approx. 6.04 million members. In addition, the quality of diagnostic testing for LB in Germany was studied. Results. In 2007 and 2008, the incident diagnosis LB was coded on average for 15,742 out of 6.04 million insured members (0.26). 20,986EIAs and 12,558 immunoblots were ordered annually for these patients. For all insured members in the outpatient sector, a total of 174,820EIAs and 52,280 immunoblots were reimbursed annually to health care providers (cost: 2,600,850). For Germany, the overall expected cost is estimated at 51,215,105. However, proficiency testing data questioned test quality and standardization of diagnostic assays used. Conclusion. Findings from this study suggest ongoing issues related to care for LB and may help to improve future LB disease management.

UR - http://www.scopus.com/inward/record.url?scp=84855583397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855583397&partnerID=8YFLogxK

U2 - 10.1155/2012/595427

DO - 10.1155/2012/595427

M3 - Article

VL - 2012

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

M1 - 595427

ER -